| Title |
Chemoprevention in Lynch syndrome
|
|---|---|
| Published in |
Familial Cancer, July 2013
|
| DOI | 10.1007/s10689-013-9650-y |
| Pubmed ID | |
| Authors |
John Burn, John C. Mathers, D. Tim Bishop |
| Abstract |
CAPP1 tested aspirin 600 mg/day and/or resistant starch 30 g/day in 200 adolescent FAP carriers. Aspirin treatment resulted in a non-significant reduction in polyp number and a significant reduction in polyp size among patients treated with aspirin for more than 1 year. CAPP2 RCT used the same interventions in 937 Lynch syndrome patients, the first RCT to have cancer prevention as the primary endpoint. Aspirin did not reduce the risk of colorectal neoplasia in a mean treatment period of 29 months but double blind post intervention follow-up has revealed 48 participants developed 53 CRCs. Per protocol analysis showed 63% fewer colon cancers with aspirin (p = 0.008) apparent from 4 years, with a similar effect on other LS cancers. Resistant starch was not beneficial at long term followup. CAPP3 will involve a double blind dose non-inferiority trial comparing 100, 300 or 600 mg daily in 3,000 gene carriers. We can now recommend aspirin in people at high risk of colorectal cancer. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 93 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 93 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 15 | 16% |
| Researcher | 12 | 13% |
| Student > Master | 11 | 12% |
| Student > Ph. D. Student | 10 | 11% |
| Student > Postgraduate | 8 | 9% |
| Other | 20 | 22% |
| Unknown | 17 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 41% |
| Agricultural and Biological Sciences | 13 | 14% |
| Biochemistry, Genetics and Molecular Biology | 8 | 9% |
| Nursing and Health Professions | 4 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Other | 8 | 9% |
| Unknown | 18 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 July 2013.
All research outputs
#14,172,739
of 22,715,151 outputs
Outputs from Familial Cancer
#292
of 558 outputs
Outputs of similar age
#111,304
of 197,951 outputs
Outputs of similar age from Familial Cancer
#4
of 9 outputs
Altmetric has tracked 22,715,151 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 558 research outputs from this source. They receive a mean Attention Score of 4.2. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,951 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.